What healthcare professionals risk when participating in or recommending psychedelics

Last reviewed: August 29, 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed physicians, therapists, nurses, psychologists, social workers, naturopaths, pharmacists, and other healthcare professionals who want to understand the professional license, employment, and liability risks of personally accessing psychedelic services or recommending them to patients.

The short answer

The risks a healthcare professional faces from psychedelic involvement depend on which activity is contemplated. Accessing Oregon’s licensed psilocybin program as a client, recommending it to patients, obtaining a facilitator license, and working at a service center each carry different risk profiles. HB 2387 (effective January 1, 2026) substantially reduced board discipline risk for licensed professionals regulated by seven specified Oregon boards — but it does not cover boards outside those seven, does not reach federal employment, and does not insulate against malpractice claims, employer policy consequences, or the specific risks that arise from impaired practice. Understanding which risks apply to which activities is the starting point for any healthcare professional considering involvement.

Accessing psilocybin services as a client

ORS 676.190(4)(c), amended in 2025, prohibits Oregon health professional licensing boards from disciplining a licensee solely because the licensee used psilocybin pursuant to ORS 475A, provided the licensee did not practice while impaired. This protection covers the act of accessing Oregon’s licensed program as a client — not facilitating, not recommending, just participating as a client.

The protection has important limits. It applies to health professional licensing boards governed by ORS 676.190 — not to every board that licenses healthcare-adjacent professionals. It prohibits discipline solely for the use — meaning that psilocybin access could still be relevant if combined with other conduct, such as impaired practice, a pattern of substance use that raises fitness concerns, or conduct during or after a session that implicated professional obligations. A health professional who accesses psilocybin services and then provides care while still experiencing residual effects faces exposure for the impaired practice, not for the access itself.

The residual effect window matters. Psilocybin’s acute effects last six to eight hours. Residual effects including fatigue, altered perception, and emotional sensitivity can continue one to two days following a full-dose session. A healthcare professional who returns to patient care the morning after a session without adequate recovery time has created impaired practice exposure regardless of the state-law protection for the underlying access.

Recommending psilocybin services to patients

Under ORS 475A.338(2)(a), clinicians regulated by the seven HB 2387 boards are protected from board discipline for discussing psilocybin services as a treatment option. The seven boards are: the Oregon Board of Licensed Professional Counselors and Therapists; the Oregon Board of Naturopathic Medicine; the Oregon Board of Psychology; the Oregon Medical Board; the Oregon State Board of Nursing; the State Board of Licensed Social Workers; and the State Board of Pharmacy.

The discussion protection forecloses board discipline for the conversation itself. It does not eliminate malpractice exposure if the recommendation was negligent — a clinician who recommends psilocybin services without reviewing the patient’s medication list, flagging a lithium contraindication, or accurately representing the evidence base may face a civil claim even though no board discipline is possible. See Malpractice exposure for clinicians involved in psychedelic services for that analysis.

Healthcare professionals regulated by boards not named in HB 2387 — occupational therapists (pending HB 4040), physical therapists (also pending HB 4040 as of early 2026), dentists, chiropractors, radiologic technologists, and others — do not have the statutory discussion protection. Their boards may have issued their own guidance, or may not have addressed the question. A professional regulated by an unlisted board should consult their specific board before engaging in clinical psilocybin conversations.

Obtaining a facilitator license and providing psilocybin services

HB 2387 prohibits the seven named boards from disciplining their licensees for holding an OPS facilitator license or for lawfully providing psilocybin services as a licensed facilitator. The protection requires that the clinician hold both a current professional license and an OPS facilitator license, notify OHA in the prescribed form before operating under dual licensure, and not provide healthcare or behavioral health services during the administration session.

The notification requirement is mandatory — dual licensure protection is not automatic upon holding both licenses. A clinician who operates as a dual-licensed facilitator without completing the required OHA notification is not within the HB 2387 framework.

The administration session carve-out is the most significant remaining risk for dual-licensed facilitators. A physician or therapist who provides clinical services during an administration session — clinical assessment, psychotherapeutic direction, diagnostic conclusions — has violated OAR 333-333-5130(2) and is subject to OPS discipline and board cross-referral under HB 2387’s information-sharing provisions simultaneously. The information-sharing provisions mean an OPS investigation may trigger scrutiny by the professional board, and vice versa.

Federal employment and federally funded workplaces

HB 2387 is Oregon state law. It protects Oregon professional licenses from Oregon board discipline. It has no effect on federal employment eligibility, federal agency policy, or the Controlled Substances Act.

Clinicians who work for the VA healthcare system, at federally qualified health centers, or at institutions operating under federal research grants face a risk analysis that runs through their specific employment context and federal funding conditions rather than through Oregon board discipline rules. A VA physician who also holds an OPS facilitator license and provides psilocybin facilitation outside VA hours is not violating the CSA in their personal capacity — facilitators do not possess psilocybin as a matter of how the licensed program works — but whether that outside work implicates VA employment policies, fitness-for-duty standards, or federal drug-free workplace rules has not been authoritatively resolved as of early 2026. A clinician in this situation needs specific legal advice before proceeding.

Employer drug-free workplace policies

Healthcare employers — hospitals, group practices, institutional employers — may maintain drug-free workplace policies that extend to outside employment involving federally scheduled substances. Psilocybin’s Schedule I status means a policy written to prohibit involvement with federally illegal substances could reach facilitator work in the Oregon program. Oregon law offers no counterweight here: the state has no statute protecting employees from discipline for off-duty psilocybin use, and nothing in Oregon law limits an employer’s ability to write and enforce a policy keyed to federal drug schedules. A clinician considering facilitator work while employed by a healthcare organization should review their employment agreement and their employer’s conduct policies before proceeding.

Malpractice insurance

Standard professional liability policies for healthcare providers frequently exclude coverage for work involving Schedule I substances. A clinician who provides psilocybin facilitation under dual licensure, pre-session medication management, or integration therapy without confirming coverage is personally exposed for any claim arising from that work. Specialty psychedelic professional liability coverage is available through carriers including TheraCover, Oath Cannabis Insurance, Relm Insurance, and AlphaRoot. A clinician should confirm in writing with their existing carrier whether any psilocybin-adjacent clinical work is covered before beginning.

Security clearances

A clinician who holds a federal security clearance and obtains an OPS facilitator license — thereby engaging professionally with a Schedule I substance — faces a clearance adjudication question that has not yet been definitively resolved. Facilitator work does not typically involve the clinician personally consuming psilocybin, but it does involve professional participation in an activity centered on a federally scheduled substance. As of early 2026, no published security clearance adjudication has addressed the OPS facilitator license specifically. A clinician with a clearance should consult a security clearance attorney before obtaining a facilitator license. See Could a security clearance, federal job, or professional license be affected by psychedelic use? for fuller treatment.

When public information may be enough

ORS 676.190(4)(c) and ORS 475A.338 are publicly available through the Oregon Legislative Assembly. OPS publishes its HB 2387 Dual Licensure Fact Sheet at oregon.gov/psilocybin. Each of the seven named boards may publish its own guidance on HB 2387 — available on each board’s website.

When you should speak with a lawyer

A clinician who works in a federally funded context and wants to understand whether board protections translate to their employment situation should get legal advice before taking any step beyond patient discussion. A clinician whose board is not among the seven named in HB 2387 and who wants to discuss psilocybin with patients or obtain a facilitator license should consult an attorney and their specific board before proceeding. A clinician who has received a board inquiry or patient complaint related to psilocybin involvement should retain counsel before responding.

You might also want to read

• Could psychedelic participation affect my job, career, or professional license?
• Dual licensure: what HB 2387 changed for Oregon clinician-facilitators
• Malpractice exposure for clinicians involved in psychedelic services
• Could a security clearance, federal job, or professional license be affected by psychedelic use?
• Can I be fired for participating in a legal psilocybin program?